KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.

George Lau, Bruno Sangro, Ann-Lii Cheng, Masatoshi Kudo, Robin Kate Kelley, Won Young Tak, Antonio Gasbarrini, Maria Reig, Ho Yeong Lim, David Tougeron, Enrico N De Toni, Vincent C Tam, Kabir Mody, Jun Gong, Oxana V Crysler, Wattana Sukeepaisarnjaroen, Oleg Lipatov, Manabu Morimoto, Isabelle Archambeaud, Valentina Burgio, Le Thi Tuyet Phuong, Yee Chao, Jean-Marie Peron, Marie-Luise Berres, Yoo-Joung Ko, Di Ran, Mallory Makowsky, Alejandra Negro, Ghassan K Abou-Alfa

Hepatology 83(3) 484-496

PMID40384092
PMCIDPMC12904228
DOI10.1097/HEP.0000000000001385
发表日期2025-05-19
入排依据:主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
摘要

摘要

BACKGROUND AND AIMS: In the global phase III HIMALAYA study in unresectable HCC, STRIDE significantly improved overall survival (OS) versus sorafenib; durvalumab was noninferior to sorafenib. Immune checkpoint inhibitor studies have shown an association between the occurrence of immune-mediated adverse events (imAEs) and improved OS. We assessed potential associations between the occurrence of imAEs and OS, and temporal patterns of imAEs, in HIMALAYA. APPROACH AND RESULTS: OS in participants who did and did not experience imAEs and the frequency and timing of imAEs were assessed for STRIDE and durvalumab in the safety analysis set of HIMALAYA. imAEs occurred in 139/388 (35.8%) and 64/388 (16.5%) participants with STRIDE and durvalumab, respectively; most were low grade. OS HRs (95% CI) in participants who experienced imAEs versus those who did not were 0.73 (0.56-0.95) for STRIDE and 1.14 (0.82-1.57) for durvalumab. The 36-month OS rate (95% CI) for STRIDE was 36.2% (28.1-46.7) and 27.7% (22.4-34.2) in participants who did and did not experience imAEs, respectively. The most common imAE category with STRIDE was endocrine events (16.5%). Most imAEs occurred ≤3 months after treatment initiation. CONCLUSIONS: Participants who experienced imAEs with STRIDE had a numerical improvement in OS versus those who did not, which was not observed for durvalumab. Long-term OS with STRIDE was observed regardless of imAEs. Most imAEs were low grade, manageable, and occurred in the first 3 months after treatment initiation. Results continue to support the benefits of STRIDE in a diverse population that reflects unresectable HCC globally.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

FIGURE 3

FIGURE 3 Overall survival by immune-mediated adverse event occurrence for (A) STRIDE and (B) durvalumab in the safety analysis set. a OS HRs and 95% CIs were calculated using Cox modeling, with imAEs as a time-varying covariate to properly account for immortal time bias and stratified by macrovascular invasion (yes or no), etiology of liver disease (HBV or HCV or other/nonviral), and Eastern Cooperative Oncology Group performance status (0 or 1) for participants with versus without imAEs of any grade. Adverse events were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Abbreviations: CI, confidence interval; HR, hazard ratio; imAE, immune-mediated adverse event; OS, overall survival; STRIDE, Single Tremelimumab Regular Interval Durvalumab.

_A_

Overall Survival

FIGURE 3 · Panel _A_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _A_ 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
_B_

Overall Survival

FIGURE 3 · Panel _B_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel _B_ 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
FIGURE 1FIGURE 1 Study profile. a Pre-planned analysis of study 22 demonstrated that T75+D did not meaningfully differentiate from durvalumab monotherapy in terms of efficacy, and toxicity was slightly increased. Thus, enrollment to T75+D in HIMALAYA was closed, and the protocol was amended to randomly assign participants 1:1:1 to STRIDE, durvalumab, or sorafenib. Abbreviations: imAE, immune-mediated adverse event; OS, overall survival; STRIDE, Single Tremelimumab Regular Interval Durvalumab; T75+D, 75 mg of tremelimumab every 4 weeks for 4 doses plus 1500 mg of durvalumab every 4 weeks.
非 KM Figure
FIGURE 2FIGURE 2 Immune-mediated adverse event Preferred Terms in the (A) STRIDE and (B) durvalumab arms of the safety analysis set. a a Preferred Term was as reported by the investigator. imAEs that occurred in ≥1.0% of participants in the STRIDE or durvalumab monotherapy treatment arms are shown. Adverse events were graded per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Preferred terms are based on MedDRA version 23.1. Abbreviations: imAE, immune-mediated adverse event; MedDRA, Medical Dictionary for Regulatory Activities; STRIDE, Single Tremelimumab Regular Interval Durvalumab.
非 KM Figure
FIGURE 4FIGURE 4 Time to onset and time to resolution of the most common imAEs by Preferred Term in the (A) STRIDE arm and in the (B) durvalumab arm in the safety analysis set. The time to onset was from the first dose of treatment. The time to resolution was from the imAE onset. imAEs with ≥5 total events across the STRIDE and durvalumab arms are included. Preferred terms are based on MedDRA version 23.1. a Arthralgia (n=4), polymyalgia rheumatica (n=3), and vasculitis (n=1). b Percent calculated as the number of participants with imAEs that were resolved out of the total number of participants with imAEs that occurred. c Arthralgia. Abbreviations: imAE, immune-mediated adverse event; MedDRA, Medical Dictionary for Regulatory Activities; mTTO, median time to onset; mTTR, median time to resolution; n, number of participants with an event; STRIDE, Single Tremelimumab Regular Interval Durvalumab.
非 KM Figure